What Is Testosterone (Total, Female)? Normal vs Optimal Range Explained

The lab reference range of 8–60 ng/dL spans an enormous range for a hormone that plays critical roles in female energy, libido, muscle maintenance, bone density, and cognitive sharpness. Women produce testosterone from three sources: roughly 25 percent from the ovaries, 25 percent from the adrenal glands, and 50 percent from peripheral conversion of precursor hormones like DHEA-S. A total testosterone of 15 ng/dL passes the lab flag but sits well below the threshold where most premenopausal women feel energetic and sexually responsive. The CTD catalogs over 1,600 chemical interactions affecting androgen receptor gene pathways in both sexes, underscoring that female testosterone biology is just as complex as male—just operating at lower absolute levels. The lower end of the lab range captures postmenopausal and elderly women whose testosterone has declined naturally, which distorts what a healthy premenopausal woman should expect.

Female testosterone declines approximately 50 percent between age 20 and menopause, making it one of the earliest hormonal changes of aging—predating the decline in estrogen and progesterone. PubMed indexes over 8,000 publications on female testosterone, with consistent findings that low testosterone in women is underrecognized because most practitioners only test it when investigating PCOS-related androgen excess. A woman in her mid-thirties presenting with fatigue, loss of motivation, reduced libido, and declining muscle tone may have a total testosterone of 20 ng/dL—technically normal but functionally insufficient. The critical nuance is that total testosterone alone can be misleading: oral contraceptives raise SHBG two to four times, which binds testosterone tightly, so free testosterone can be critically low even when total testosterone appears adequate.

On the high end, total testosterone above 60 ng/dL in women warrants investigation for polycystic ovary syndrome (PCOS), congenital adrenal hyperplasia, or rarely, androgen-secreting tumors. FAERS documents adverse event reports linking multiple medication classes to androgen disruption in women, including corticosteroids that suppress adrenal testosterone production and GnRH agonists used in endometriosis treatment. For accurate assessment, total testosterone should always be interpreted alongside free testosterone and SHBG. A woman on oral contraceptives with total testosterone of 35 ng/dL (looks optimal) but SHBG of 200 nmol/L may have a free testosterone near zero—the total number masks the true hormonal deficit that is driving her symptoms.